Last reviewed · How we verify
EFV+3TC+TDF
efv+3tc+tdf is a combination of three antiretroviral medications, efavirenz (efv), lamivudine (3tc), and tenofovir disoproxil fumarate (tdf), originally developed by Gilead Sciences. It is a small molecule modality, but its target and drug class are not specified. The commercial status of efv+3tc+tdf is not provided, but it is owned by Gilead Sciences. This combination is used to treat HIV-1 infection, but the exact mechanism of action is not detailed. Key safety considerations are not specified.
At a glance
| Generic name | EFV+3TC+TDF |
|---|---|
| Sponsor | Gilead Sciences |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) (PHASE2)
- Good-first: B/F/TAF As First-line ART
- Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (PHASE2,PHASE3)
- ANRS 12372 MODERATO Study (PHASE3)
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants (PHASE2)
- DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EFV+3TC+TDF CI brief — competitive landscape report
- EFV+3TC+TDF updates RSS · CI watch RSS
- Gilead Sciences portfolio CI